<code id='27FFEB0886'></code><style id='27FFEB0886'></style>
    • <acronym id='27FFEB0886'></acronym>
      <center id='27FFEB0886'><center id='27FFEB0886'><tfoot id='27FFEB0886'></tfoot></center><abbr id='27FFEB0886'><dir id='27FFEB0886'><tfoot id='27FFEB0886'></tfoot><noframes id='27FFEB0886'>

    • <optgroup id='27FFEB0886'><strike id='27FFEB0886'><sup id='27FFEB0886'></sup></strike><code id='27FFEB0886'></code></optgroup>
        1. <b id='27FFEB0886'><label id='27FFEB0886'><select id='27FFEB0886'><dt id='27FFEB0886'><span id='27FFEB0886'></span></dt></select></label></b><u id='27FFEB0886'></u>
          <i id='27FFEB0886'><strike id='27FFEB0886'><tt id='27FFEB0886'><pre id='27FFEB0886'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:Wikipedia    Page View:98596
          Senate Finance Committee Chair Ron Wyden (D-Ore.) Leah Millis/Pool via AP

          WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to clamp down on drug middlemen, but kicked the can down the road on some of the more challenging policies.

          The bill would offer some more transparency into the business practices of pharmacy benefit managers, ensure PBMs aren’t skimming off of the money they send to insurers, prohibit them from overcharging insurers, and ensure certain fees in the Medicare program aren’t tied to a drug’s price.

          advertisement

          “It’s pretty hard to get 26 votes around here,” Finance Chair Ron Wyden (D-Ore.) said after the vote. “So we’re thrilled.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          A preacher's new calling: Diversifying neuroscience research
          A preacher's new calling: Diversifying neuroscience research

          TheauthorpreachingatUnionBaptistChurchinBaltimore.CourtesyEvelynJ.ChatmonWhenIwasthepastorofalargeBa

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Gene therapy denied for Afghan refugee whose father aided U.S.

          ThePashaichildren(fromleft):Abubakar,Mohammad,andSufyan.Illustration:STAT;PhotoCourtesyOnasweltering